Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pilot study of lanadelumab in hereditary angioedema with normal C1 inhibitor
2018-004136-30Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanadelumab in Hereditary Angioedema With Normal C1-Inhibitor (HAE-nl-C1-INH), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Change in Angioedema Activity Score (AAS). Started Mar 2019; status: completed.
02
Drugs
lanadelumab
03
Conditions
Hereditary Angioedema With Normal C1-Inhibitor (HAE-nl-C1-INH)
Beyond the preview
Go deeper on 2018-004136-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004136-30.